Uroxatral: Targeted Relief for Benign Prostatic Hyperplasia
Uroxatral
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.73 | $52.00 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $104.00 $85.00 (18%) | 🛒 Add to cart |
| 90 | $1.31 | $156.00 $118.00 (24%) | 🛒 Add to cart |
| 120 | $1.20 | $208.00 $144.00 (31%) | 🛒 Add to cart |
| 180 | $1.10 | $312.00 $198.00 (37%) | 🛒 Add to cart |
| 270 | $1.00 | $468.00 $270.00 (42%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $624.00 $324.00 (48%) | 🛒 Add to cart |
Synonyms | |||
Uroxatral (alfuzosin HCl) is a selective alpha-1 adrenergic receptor antagonist specifically indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). It works by relaxing smooth muscle in the prostate and bladder neck, which improves urine flow and reduces BPH symptoms. This medication is designed for ease of use with a once-daily, extended-release formulation that can be taken with or without food, offering both efficacy and convenience for appropriate patients under medical supervision.
Features
- Contains alfuzosin hydrochloride as the active ingredient
- Extended-release tablet formulation for 24-hour symptom control
- 10 mg strength, administered once daily
- Does not require dose titration in most patients
- Can be taken with or without food
- Manufactured under strict quality control standards
Benefits
- Significantly improves urinary flow rate and reduces residual urine volume
- Provides relief from bothersome BPH symptoms including weak stream, hesitancy, and nocturia
- Once-daily dosing supports medication adherence and consistent symptom management
- Rapid onset of action with many patients experiencing improvement within weeks
- Does not typically require dosage adjustment based on age
- Specifically targets alpha-1 receptors in prostate and bladder neck with selectivity
Common use
Uroxatral is primarily prescribed for the management of symptomatic benign prostatic hyperplasia (BPH) in adult males. It addresses both obstructive symptoms (poor stream, straining, incomplete emptying) and irritative symptoms (frequency, urgency, nocturia) associated with BPH. The medication is typically used as part of a comprehensive BPH management plan that may include regular monitoring, lifestyle modifications, and in some cases, combination therapy with 5-alpha reductase inhibitors for patients with significantly enlarged prostates.
Dosage and direction
The recommended dosage of Uroxatral is one 10 mg extended-release tablet taken orally once daily, immediately after the same meal each day. Tablets should be swallowed whole and not crushed, chewed, or divided. Administration with food enhances bioavailability and ensures consistent drug absorption. Treatment should be initiated under physician supervision, and patients should be advised to take the medication at approximately the same time daily to maintain steady-state concentrations. No initial dose titration is required for most patients.
Precautions
Patients should be screened for prostate cancer before initiating and during Uroxatral therapy, as BPH symptoms may mimic those of prostate cancer. Orthostatic hypotension with or without symptoms (dizziness, lightheadedness) may occur within hours after administration, particularly during initial treatment or dose increases. Patients should avoid situations where injury could result should syncope occur. Intraoperative floppy iris syndrome has been observed during cataract surgery in patients taking alpha-1 blockers; ophthalmologists should be informed prior to surgery. Regular monitoring of blood pressure is recommended, especially during initial treatment.
Contraindications
Uroxatral is contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride or any component of the formulation. It is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh categories B and C) due to significantly increased alfuzosin exposure. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) is contraindicated. The medication is not indicated for use in women or children, and should not be used in patients with a history of orthostatic hypotension.
Possible side effects
Common side effects (≥2%) include dizziness (6.3%), upper respiratory tract infection (3.2%), headache (3.2%), fatigue (3.0%), and constipation (1.7%). Less frequent but potentially serious adverse reactions include orthostatic hypotension (0.4%), syncope (0.4%), and priapism (rare). Gastrointestinal disturbances such as abdominal pain, dyspepsia, and nausea may occur in some patients. Most adverse reactions are mild to moderate in severity and often diminish with continued therapy. Patients should report persistent or concerning symptoms to their healthcare provider.
Drug interaction
Uroxatral is primarily metabolized by CYP3A4 and should not be coadministered with potent CYP3A4 inhibitors. Concomitant administration with other alpha-adrenergic blocking agents may result in enhanced hypotensive effects. Antihypertensive medications and nitrates may potentiate the hypotensive effects of alfuzosin. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) may enhance the blood pressure-lowering effects. Careful monitoring is recommended when Uroxatral is administered with moderate CYP3A4 inhibitors, and dose adjustment may be necessary.
Missed dose
If a dose of Uroxatral is missed, patients should take it as soon as remembered on the same day. If missed entirely for that day, the patient should skip the missed dose and resume the regular dosing schedule the following day. Patients should not take a double dose to make up for a missed dose. Maintaining a consistent dosing schedule relative to meals is important for optimal therapeutic effect. Patients experiencing multiple missed doses should consult their healthcare provider before resuming therapy.
Overdose
In case of suspected overdose, supportive care should be instituted with particular attention to maintaining blood pressure and heart rate. Expected manifestations would include pronounced hypotension, possibly accompanied by dizziness, lightheadedness, tachycardia, or syncope. Active cardiovascular support may be required, with blood pressure restoration being the primary concern. Dialysis may not be effective due to high protein binding of alfuzosin. Patients should seek immediate medical attention if overdose is suspected, and bring the medication container for identification.
Storage
Store Uroxatral tablets at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication that is no longer needed or has expired according to local guidelines for medication disposal.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Uroxatral is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient responses may vary, and treatment decisions should be based on a healthcare provider’s assessment of the patient’s specific medical condition, history, and needs. Patients should not initiate, discontinue, or change dosage without consulting their physician.
Reviews
Clinical studies demonstrate that Uroxatral provides significant improvement in BPH symptoms, with International Prostate Symptom Score (IPSS) improvements of approximately 4-5 points from baseline. Patients report meaningful improvements in quality of life measures, particularly regarding nocturia and urinary urgency. The convenience of once-daily dosing without food restrictions is frequently cited as a positive aspect of therapy. Most adverse effects are reported as mild and transient, with discontinuation rates due to side effects typically below 5% in clinical trials. Long-term studies support maintained efficacy with continued use.